Abstract. Considering the diversity in physiology between species and the numerous dosage forms that exist in veterinary drug products, there are numerous complex issues that arise from the development and regulation of veterinary drugs for food-producing and companion animals. Generic drugs are no exception. The main objective of this article is to illustrate the current important similarities and differences between international veterinary bioequivalence guidelines. It is concluded that since important differences are found, these may lead to barriers in international data exchange and scientific confusion, hence fostering the need for a harmonization effort in developing consistent guidelines based on sound pharmacological and statistical principles for the approval of veterinary generic drugs around the world.
INTRODUCTION
Consistent with the diversity in physiology that exists across veterinary species and because of the unique formulations and methods of drug administration associated with veterinary drugs, there are numerous complex issues that are unique to the regulation of these drug products. Accordingly, the determination of product bioequivalence (BE) in animal species can present a host of statistical, logistical and regulatory challenges.
International differences in addressing these challenges and in defining the criteria for determining BE may lead to barriers in international data exchange and scientific confusion. In consideration of these scenarios, an effort to harmonize the critical BE parameters is necessary to establish consistency within the scientific and regulatory communities. In the foreshadowing of international harmonization, it is appropriate to demonstrate the numerous similarities and few differences in veterinary BE guidelines between the regulatory authorities around the world. Thus, the purpose of this article is to highlight, in a tabulated form, important international criteria for the consideration of granting biowaivers and for the demonstration of BE for veterinary drug products intended for both foodproducing and companion animals.
MATERIALS AND METHODS
Tabulation of similarities and differences in veterinary BE guidelines between regulatory authorities was possible by referring to government websites (1-6) from Australia, Canada, Europe, Japan, New Zealand and the United States, and by consulting regulatory agents from each country. Table I is a comparative table of the main criteria for granting biowaivers of in vivo BE studies by the Australian Pesticides and Veterinary Medicines Authority (APVMA), the Health Canada's Veterinary Drugs Directorate (VDD), the European Medicines Agency (EMA), Japan's Ministry of Agriculture, Forestry and Fisheries/National Veterinary Assay Laboratory (MAFF/NVAL), New Zealand's Ministry of Agriculture and Forestry/Agricultural Chemicals and Veterinary Medicines (MAF/ACVM) and the US Food and Drug Administration/Center for Veterinary Medicine (FDA/ CVM). Table II is a summary of the main similarities and differences in BE guidelines for the conduct of blood level studies between these same regulatory authorities.
RESULTS

DISCUSSION
Currently, as shown in the above tables, the registration requirements for demonstrating BE for veterinary 1 Table II is that even if the "identical" reference product is used across jurisdictions, generally, these products are uniquely manufactured for distribution within a specific region. In this regard, even if formulations are considered identical, international differences in product specifications, manufacturing equipment and manufacturing process could potentially lead to international variations in product quality and performance. Therefore, even though a sponsor's globally marketed product contains the same ingredients (active and inactive), dosage form and strength, and indications, there is a perceived potential for differences in the in vivo bioavailability characteristics of these products across the various geographic regions. For this reason, regulatory authorities within each jurisdiction generally require that BE studies be conducted using the reference product that is marketed within their own jurisdiction, necessitating an individual BE study for each country. However, it should be noted that there are no published studies that explore the in vivo similarities and differences between veterinary reference products marketed across various geographic locations.
A first step in this assessment could simply be the comparison of in vitro product performance and specifications. It is possible that international concerns about the quality and performance differences between globally marketed reference products far outweigh the reality of these concerns (7) . At this time, Canada's VDD Guidance for Industry: Preparation of Abbreviated New Drug Submissions: Generic Drugs (2010) requests a side-by-side comparison of physicochemical properties between a foreign-registered reference product and the same marketed Canadian Reference Product (CRP) to assess the appropriateness of the use of that foreign reference product instead of the CRP in the conduct of a BE study for the purpose of a Canadian approval of a generic drug product. New Zealand's MAF/ACVM may also accept studies conducted on overseas reference products if acceptable evidence is provided that the reference product is equivalent to the NZ registered product. What constitutes acceptable evidence is dependent on the formulation type.
CONCLUSION
As pharmaceutical sciences move forward, the animal health industry is witnessing a rapid evolution in veterinary therapeutics and a growing need for ensuring international harmonization to accommodate the burgeoning global marketplace. The first step in support of this evolving therapeutic landscape is efforts to obtain a universal definition of BE, along with agreement on the underlying pharmacokinetic, statistical and bioanalytical principles essential to BE assessments. Such a harmonization process will serve as an important first step towards pharmaceutical globalization and will help reduce or eliminate potential confusion on the application of BE concepts to veterinary medicines.
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